



**DOCKET NO.: ISHT-1004/HTS-0016US.P1**

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In Re Application of:**

**Kenneth W. Dobie and Erich Koller**

**Confirmation No.: 2946**

**Application No.: 10/714,796**

**Group Art Unit: 1635**

**Filing Date: November 17, 2003**

**Examiner: Not Yet Assigned**

**For: ANTISENSE MODULATION OF KINESIN-LIKE 1 EXPRESSION**

**EXPRESS MAIL LABEL NO: EV631244260US**

**DATE OF DEPOSIT: January 23, 2006**

**EV631244260US**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

- ☐ Certification in Accordance with § 1.97(e) is attached; or
- ☐ The fee of **\$180.00** as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of **\$180.00** as set forth in § 1.17(p).

- ☒ Copies of reference numbers **14 - 16** listed on the attached Form PTO-1449 are enclosed herewith.

- ☒ Copies of reference numbers **17 - 18** on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).

- ☐ Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.


- ☐ The relevance of those listed references which are not in the English language is as follows:

There are no listed references which are not in the English language.

The references cited on the attached PTO-1449 form were cited in the International Search Report Written Opinion dated December 27, 2005 that was received in the corresponding PCT application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: January 23, 2006

  
Phillip A. Singer  
Registration No. 40,176

WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. ISHT-1004/HTS-0016US.P1		Application No. 10/714,796
	Applicant Kenneth W. Dobie and Erich Koller		
	Filing Date November 17, 2003		Group 1635
	Confirmation No. 2946		
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	14	Agrawal S., et al., "Antisense therapeutics: is it as simple as complementary base recognition?" <i>Molecular Med. Today</i> , <b>2000</b> , 6, 72-81	
	15	Branch, A.D., "A good antisense molecule is hard to find," <i>TIBS</i> , <b>1998</b> , 23, 45-50	
	16	Jen, K.-Y., et al., "Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies," <i>Stem Cells</i> , <b>2000</b> , 18, 307-319	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office				Docket No. ISHT-1004/HTS-0016US.P1		Application No. 10/714,796	
				Applicant Kenneth W. Dobie and Erich Koller			
				Filing Date November 17, 2003		Group 1635	
				Confirmation No. 2946			
<b>U. S. PATENT DOCUMENTS</b>							
<b>Examiner Initial</b>		<b>Document No.</b>	<b>Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	
	17	5,801,154	09/01/98	Baracchini, et al.	514	44	
	18	2004/0009156 A1	01/15/04	Reinhard, et al.	424	93.21	
<b>FOREIGN PATENT DOCUMENTS</b>							
<b>Examiner Initial</b>		<b>Document No.</b>	<b>Date</b>	<b>Country</b>	<b>Translation</b>		
					<b>YES</b>	<b>NO</b>	
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>			